Combining gefitinib (a specific EGFR inhibitor) and OSI-906 (a dual inhibitor of InsR/IGF-1R) was more effective than either agent alone in the inhibition of subcutaneous glioblastoma xenografts58. Here, INSR is linked to glioblastoma.